Literature DB >> 7903373

Pharmacokinetics of chlorimipramine, chlorpromazine and their N-dealkylated metabolites in plasma of healthy volunteers after a single oral dose of the parent compounds.

L Della Corte1, M Valoti, M Palmi, M G Giovannini, G P Sgaragli.   

Abstract

A single oral dose of 0.7 mg kg-1 chlorimipramine (n = 18) and chlorpromazine (n = 16) was given to each subject 45 days apart and plasma concentrations of parent drugs and their monodesmethyl and didesmethyl metabolites were measured by GC. Ingestion of chlorimipramine resulted in an area under the plasma concentration-time curve (AUC0-24) for parent drug plus metabolites 5-fold higher than that observed in the same subjects following chlorpromazine intake (600 +/- 87 and 124 +/- 14 ng mL-1, respectively). Plasma chlorimipramine levels reached a mean peak value of 43.8 ng mL-1, which occurred 2 h after administration. Desmethyl metabolite kinetics of chlorimipramine appeared to be elimination rate-limited and those of chlorpromazine appeared to be formation-rate-limited. The response to single doses of these two drugs in healthy subjects highlights the two distinct dispositional processes involved, thus offering pharmacokinetic explanation of the hitherto empirical discrepancy in dosage levels in chronic treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903373     DOI: 10.1111/j.2042-7158.1993.tb05694.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  2 in total

1.  The Impact of the Antipsychotic Medication Chlorpromazine on Cytotoxicity through Ca2+ Signaling Pathway in Glial Cell Models.

Authors:  Che-Sheng Chu; Yung-Shang Lin; Wei-Zhe Liang
Journal:  Neurotox Res       Date:  2022-04-19       Impact factor: 3.911

2.  Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors.

Authors:  Vladimir P Grinevich; Roger L Papke; Patrick M Lippiello; Merouane Bencherif
Journal:  Neuropharmacology       Date:  2009-05-28       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.